TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02596854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurological MRI
Description: Neurological MRI image collection
Study: NCT04400396

Intervention type: DIETARY_SUPPLEMENT
Intervention: standard HM fortification
Description: Based on the assumed energy and macronutrient composition of HM, the commercial multi-component HM fortifier was added, in order to compensate identified nutritional deficits.

Intervention type: DIETARY_SUPPLEMENT
Intervention: target HM fortification
Description: Based on the measured energy and macronutrient composition of HM, modular protein and fat supplements are added, in addition to the commercial multi-component HM fortifier, in order to correct identified specific nutritional deficits. For this purpose, an Excel program to calculate modular protein and fat supplements to be added to fortified HM was developed and registered (Nona R, Cardoso M, Portuguese Directorate of Intellectual Property Services, IGAC-DSPI, nº 480/2020, 26 February 2020)
Study: NCT02750891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-7888
Description: Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks
Study: NCT04480905

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tape
Description: The 3M™ Soft Cloth Tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
Study: NCT01745159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study: NCT04635917

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional dietary advice
Description: Participants in the CD group will receive non-personalized, conventional dietary advice by a dietitian based on the MyPlate guidelines.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional dietary advice
Description: Participants in the CD group will receive non-personalized, conventional dietary advice by a dietitian based on the MyPlate guidelines.
Study: NCT01843387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: Single Intravenous Infusion of MPCs Dose 1 or Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: Single Intravenous Infusion of MPCs Dose 2 or Placebo
Study: NCT02946996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT04102917

Intervention type: DIAGNOSTIC_TEST
Intervention: QFR assessment
Description: The quantitative flow ratio (QFR) is a novel angiography-based method for noninvasive functional assessment of intermediate coronary lesions.
Study: NCT03196843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiotherapy
Description: Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Description: Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week
Study: NCT02449980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Surgery Group
Description: Patients will receive surgical intervention during the initial hospital admission, as previously described, for the spontaneous pneumothorax. Patients will then be admitted postoperatively and monitored until discharge criteria are met

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Initial Non-operative management
Description: Patients will receive percutaneous drainage or chest tube placement as initial management for spontaneous pneumothorax. This will be followed by an observation period until discharge criteria are met.
Study: NCT02946996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPC
Description: OPC is a derivative of grape seed extract
Study: NCT02230501

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: stringent diet regimen

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: moderate diet regimen
Study: NCT01088594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone/placebo/pioglitazone
Description: single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
Study: NCT02114346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride
Description: Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
Study: NCT00242424

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 2005-2006 trivalent inactivated influenza vaccine
Description: Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2005-2006 trivalent inactivated influenza vaccine
Description: Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.
Study: NCT01088594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone/placebo/pioglitazone
Description: single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rosiglitazone/placebo/pioglitazone
Description: single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/rosiglitazone/pioglitazone
Description: single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/rosiglitazone/pioglitazone
Description: single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/rosiglitazone/pioglitazone
Description: single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
Study: NCT04351724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine or Hydroxychloroquine
Description: Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Lopinavir/Ritonavir 200mg/50mg 2-0-2

Intervention type: OTHER
Group type: OTHER
Intervention: Best standard of care
Description: best standard of care

Intervention type: OTHER
Group type: OTHER
Intervention: Best standard of care
Description: best standard of care

Intervention type: OTHER
Group type: OTHER
Intervention: Best standard of care
Description: best standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thromboprophylaxis
Description: as local standard, most likely to be low molecular weight heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: starting dose 4mg once daily, titrated to normotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-RAS blocking antihypertensives
Description: This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: 200mg on day 1, thereafter 100mg for a total of 5-10 treatment days, according to local standards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunercept 400mg
Description: asunercept 400mg once per week, up to 4 doses in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunercept 100mg
Description: asunercept 100mg once per week, up to 4 doses in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunercept 25mg
Description: asunercept 25mg once per week, up to 4 doses in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentaglobin
Description: 7ml/kg/day for 12h for 5 days
Study: NCT02333019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Talk About Sex
Description: Multimedia web site to build parental skills in communicating with their pre-adolescnet child sex and relationships, pregnancy prevention, and risk of sexually transmitted infections.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Websites; preventing teen pregnancy
Description: Two general web sites with information about preventing teen pregnancy
Study: NCT02141139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDS (ketorolac and ibuprofen)
Study: NCT03459638

Intervention type: OTHER
Intervention: Screening for DM, ASCVD, MetS and OSAS
Description: Finger stick analysis, questionnaires and clinical measurements

Intervention type: OTHER
Intervention: Screening for DM, ASCVD, MetS and OSAS
Description: Finger stick analysis, questionnaires and clinical measurements
Study: NCT03129360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prepared in capsules to appear identical to levetiracetam.
Study: NCT03171818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
Study: NCT04098861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost/Timolol
Description: Latanoprost/Timolol Fixed Combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost/Timolol
Description: Latanoprost/Timolol Fixed Combination
Study: NCT03358134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: anti IL17 therapy (subcutaneous)
Study: NCT03759106

Intervention type: OTHER
Group type: OTHER
Intervention: home written exercise program
Description: exercises such as picking up objects, placing objects, frequently prescribed at discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation/exergame system
Description: Video games using the Kinect camera that are carried out using the impaired arm and monitored by a therapist by videoconferencing
Study: NCT00285168

Intervention type: BEHAVIORAL
Intervention: Bone Density Decision Aide
Description: Absolute 10-year Fracture Risk Report
Study: NCT03739515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCP intervention
Description: A team of HSCPs (physiotherapist, occupational therapist, medical social worker) will provide comprehensive functional assessment to older patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ED routine care
Description: ED staff including consultants and nurses will provide patients with routine ED medical care.
Study: NCT01054625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zalutumumab
Description: Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zalutumumab
Description: Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zalutumumab
Description: Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.
Study: NCT00231413

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV 16/18 L1 AS04
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 L1 AS04 Formulation 1
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 L1 AS04 Formulation 2
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 L1 AS04 Formulation 3
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 L1 AS04 Formulation 4
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 L1 AS04 Formulation 5
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 L1 AS04 Formulation 6
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
Study: NCT00565136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPAS
Description: A mesh sling permanently implanted to increase pelvic floor support
Study: NCT00119821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Reducing Diet
Description: Behavioral intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Moderate exercise implemented plus behavioral intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking Cessation
Description: Nicotine Patch in dosages given based on number of cigarettes per day smoked. 21 mg patch, 14 mg patch, 7 mg patch for total of 6 weeks duration of therapy.~NRT gum is being provided to assist with relapse prevention. At the randomization visit the participant is given one (1) box of 2mg NRT gum, which consists of (110) pieces. The participant may request up to two (2) more boxes, for a maximum of three (3) boxes per participant.
Study: NCT02640495

Intervention type: DRUG
Intervention: Intravenous Artesunate as part of standard medical practice
Description: Intravenous Artesunate 2.4 mg/kg
Study: NCT02687087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visco-ease
Description: 19.6 mg/mL of LMS-611

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological Saline
Study: NCT01520025

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET MPI imaging with 18F-Fluorodeoxyglucose
Description: Exercise Stress Testing. All patients will undergo a symptom-limited exercise treadmill test using the Bruce protocol after a 24 hour high fat, low carbohydrate diet and an overnight fast. Persantine Stress Testing: Subjects who have undergone Persantine stress protocol for the PET or SPECT will follow the same protocol. A high fat, low carbohydrate diet for 24 hours and a 12 hour overnight fast will precede the study stress scan. Anti-anginal medications will be withheld on the morning of the exercise test.~18FDG (370 mBq) will be injected at either peak exercise or within 1 hour of peak.~Patients will be imaged 60 minutes after radiotracer injection in the supine position in a Discovery 690/VCTLYSO PET system (GE Healthcare, Milwaukee, Wisconsin)
Study: NCT03677154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab Intravenous (IV)
Description: Participants in cohorts A and B will receive IV mosunetuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab Intravenous (IV)
Description: Participants in cohorts A and B will receive IV mosunetuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab Subcutaneous (SC)
Description: Participants in Cohort C will receive SC mosunetuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants in Cohort C will receive IV polatuzumab vedotin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).
Study: NCT00632333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil
Description: Escalating dose of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 will be administered by subcutaneous injection on days 15, 22, 28 and 35 of treatment cycle. Doses of each peptide are planning 0.5mg, 1mg and 3mg/body. Chemotherapy plus radiation therapy will be done as follows: fluorouracil (400mg/m2) on day1-5 and 8-12, cisplatin (40mg/m2) on days 1 and 8, radiation (2Gy) on days 1-5, 8-12 and 15-19. Two cycles of combination of chemoradiation therapy and epitope peptide vaccine therapy will be done.
Study: NCT01652664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% PQ ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol, 0.5% or 0.25% ophthalmic solution
Description: Patients 2 months to \< 3 years of age received 0.25%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Vehicle
Description: Inactive ingredients used to maintain masking
Study: NCT04444596

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Conjunctival swab and nasopharyngeal swab
Description: Both conjunctival swab and nasopharyngeal swab for SARS-COV 2 are conducted in patients with COVID-19.
Study: NCT02062762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online-MBSR
Description: 8 week mindfulness based stress reduction online
Study: NCT00003610

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: capsaicin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation therapy
Study: NCT02663843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel airway
Description: Fibreoptic intubation via i-gel airway device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air-Q airway
Description: Fibreoptic intubation via air-Q airway device
Study: NCT02062762

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive Writing Online
Description: Online distributed expressive writing intervention as active control
Study: NCT02103283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Description: Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
Study: NCT05231434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: hydration with mineral water in 10 equal portions, administered at regular intervals from the 15th minute of exercise until the end of the recovery period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic activity
Description: aerobic activity
Study: NCT01668355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Aligned Care Team (PACT)
Description: An integrated healthcare model to coordinate and address physical health needs of people with serious mental illness. This specialized PACT medical home model is designed for individuals with serious mental illness.
Study: NCT00935441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: case management with telemonitoring
Description: telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual case management
Description: telephone contact with a case manager